



## Strategy

### *First UK healthcare-housing REIT*

Civitas Social Housing was created in 2016 as the first dedicated London-listed REIT, to invest in care-based social homes and healthcare facilities. The average occupier age is 32. Income is from long-term leases, not related to occupancy. Demographic-related demand for accommodation is high. Most recently, it has extended its mandate to be able to work directly with leading care-based organisations.

### *Housing associations and care providers provide covenant support*

### *Sector in significantly rising demographic-led demand*

## Occupier outcomes, assets, evolution of the model

Civitas's housing stock provides a cost-effective alternative to hospitals for young adults with medical needs, including learning difficulties. The assets are leased out to housing associations on long-term CPI-inflating leases. Around 14% of UK social housing is represented by supported housing: a small but fast-growing segment.

### *Evolution towards higher-acuity accommodation*

The housing stock does require specific and relatively extensive re-configuration, which is structural in nature. More explanation of "adaptations" can be found [here](#). Civitas does not develop; it buys from developers and care providers, involving forward purchases. Facilities now extend to high-acuity assets. The largest – in Wales – is set to complete later this calendar year, and is an important evolution. Civitas is still not taking occupancy risk, and it enters into a long-term fixed uplift lease, but the close knowledge of the care providers and the building requirements have enabled this move into a closely allied area, with strong demand-led growth and higher-value properties. There will be further capital allocated to this higher-acuity asset class, where Civitas works closely with its selected care providers, with Civitas finding the buildings, specifying the adaptations required, and bringing in housing associations.

### *Government funding to lessees*

Funding of the lessees – the housing associations – is through housing benefit. There have been specific political policy rulings that this should not be included in changes being made into universal credit regimes.

### *Two large equity raises now fully deployed and investing towards 35% LTV target*

## Execution and dividends

£350m equity capital was raised at an oversubscribed November 2016 IPO, and a subsequent secondary raise of £302m took place a year later. The pre-results update confirmed total invested capital since IPO reaching £789m, made up of 613 properties, fully let to 15 housing associations, supported by 117 care providers in 164 local authorities. There are over 4,200 individual tenants, with a market share of under 1%.

### *Wide range of counterparts*

### *Competitive cost of debt*

Average cost of debt stood at 2.46% at the end of fiscal 2020, with a 3.4-year term. This competitive cost of debt indicates covenant strength.

### *Raised dividend target*

With dividends expected to be 100% covered, the target growth for 2021 has been raised, with the dividend expected to reach 5.4p that year.

### *Positive social impact with analysis and quantification of impact*

## Social impact

Significant positive social impact is generated. Civitas publishes a social impact report (compiled by a specialist third-party provider) twice yearly, which is worth consulting. There is more information [here](#), with the [latest version available](#).

### *Civitas's not-for-profit company to benefit society and support covenant strength*

The [Social Housing Family CIC](#) is a recently formed, not-for-profit community interest company established by Civitas, but operationally independent, whose stated aim is to enable housing associations holding Civitas leases to increase skills and experience, and to provide funding, if required, to promote enhanced performance.

## Civitas Social Housing

Government regulator's role includes support of corporate governance within housing association sector

The social housing sector is regulated by a government agency, including the specialist supported social housing that Civitas provides. The social housing sector is a stable partner for local authorities, occupiers, investors and other stakeholders. Some individual registered providers may encounter difficulties, but providers have not defaulted. Regulatory interventions assist corporate governance and are materially beneficial, especially to smaller organisations. Supported social housing is fast-growing, and many housing associations participating are specialist and moderately sized. The operational standards of the sector are high.

First sector to have COVID-19- related "Material Uncertainty" clause removed

## Valuation

At end-4Q'20 (March 2020), the net initial yield (NIY) of the portfolio stood at 5.26%. There has been an element of yield compression since the time of acquisitions following the IPO, which achieved typically 6%-plus. As we have pointed to as significant, this sector has been the first to emerge from the "Material Uncertainty Clause" that the valuers' body, RICS, mandated, in response to the pausing of real estate markets consequent to COVID-19. This points to the RICS considering there to be a deep and liquid market in this relatively young asset class. Civitas's purchases are prospectively slowing as a result of it moving towards its 35% gearing target. Incremental assets drive much more into the higher-acuity assets.

### Peer group: historical valuation ratios and share price performance

REIT	Share price (p)	Price/ EPRA NAV	Dividend yield	Share price change past 12 months
Average secure income REIT Hardman "Basket"*	95	105%	5.0%	-7.0%
Impact Healthcare	95	89%	6.5%	-15%
Target Healthcare	110	102%	6.1%	-5%
Triple Point Social Housing	99	95%	5.1%	+19%
Civitas Social Housing	110	103%	4.6%	+37%

Source: Hardman & Co Research

\*Hardman & Co published research in March 2019, "Secure income" REITs – Safe Harbour Available, and May 2020, Safer harbour REITs: an update, including a basket of 16 UK REITs that seek to generate secure income streams as their primary investment mission. A list of these REITs can be found in the [May report](#). Data are historical, and the "Basket" is estimated to see a 10% dividend cut in 2020. Data relate to the weighted average for this basket of 16 REITs, which includes Civitas Social Housing REIT.

Civitas Social Housing REIT externally managed by recently renamed Civitas Investment Management Ltd

## Managers

Civitas Social Housing REIT is externally managed by Civitas Investment Management Ltd. It is of interest that the adviser was, until recently, named Civitas Housing Advisors. Residential remains the core competence, and this has extended to work directly with the NHS and other leading care-based organisations, as well as higher- acuity accommodation and facilities.

Five non-executive independent directors of Civitas Social Housing oversee the management. Chair is Michael Wrobel, former director of the Association of Investment Companies, and a director of several investment trusts, who has 30 years' experience of investment management. The manager's CEO is Paul Bridge, a leading industry director, previously CEO of Homes for Haringey, and non-executive chairman of the Metropolitan Thames Valley Housing Association.

Fees are 1% of net assets to £250m, then tiered to run to 0.7% of net assets over £1bn.

### SWOT analysis

<b>Strengths</b>	100% rent funded from government-underpinned income streams; all leases CPI-linked, long-term; COVID-19 resilience; nil GDP correlation
<b>Weaknesses</b>	Certain lessees are small organisations – but profile has improved
<b>Opportunities</b>	Expanding into higher-acuity assets, which may have more valuation upside
<b>Threats</b>	Regulation changes; interest re-finance 2023

Source: Hardman & Co Research

## Investment conclusion

*Tested, refined, evolved model*

*Government income, but not government-guaranteed in any way*

*2019 strengthening of model*

*Income strength translates to good dividend prospects*

- ▶ This model has been refined, through expertise gained in specifying and managing clinical assets, strengthening Civitas's proposition to all stakeholders, including, importantly, Local Authorities' commissioning officers.
- ▶ It is important to note that income streams are funded by the government, but these pass through local government and the lessees, the housing associations, which are closely government-regulated but not government-guaranteed
- ▶ Civitas has re-assigned some of its leases, strengthening the mix. One small housing association constituted ca.20% of the rent roll in March 2019, and has now reduced to ca.6%. It is noteworthy and should be emphasised that this was all achieved on the same terms – rent and length of lease – as the original lease. Civitas has shown resilience in engaging with stakeholders, including the Regulator, and has “proven the model” in the past year and more.
- ▶ Civitas's income profile is particularly attractive, with long leases (well in excess of 20 years), and all income is CPI-linked and ultimately government-backed.
- ▶ It is still optimising the rent roll and gearing, but has now reached 100% dividend cover, on growing payouts per share.

### Financial summary and valuation

Year-end Mar (£m)	2018	2019	2020E	2021E	2022E
Revenue	18,606	35,738	46,310	52,180	55,560
Expenses	-8,893	-9,642	-9,640	-9,230	-9,420
Underlying EBIT (pre-revaluation)	9,713	26,096	36,670	42,950	46,140
Revaluation	30,633	3,652	8,360	10,700	17,660
Operating profit	40,346	29,748	45,030	53,650	63,800
Finance cost	-628	-3,484	-7,480	-8,750	-9,710
C share amortisation <sup>1</sup>	-2,792	-6,400	0	0	0
Pre-(and post-) tax profits	36,926	19,864	37,550	44,900	54,090
EPRA earnings <sup>2</sup>	9,085	22,612	29,190	34,200	36,430
EPRA EPS (p)	1.44	3.63	4.69	5.50	5.86
Dividend per share (p)	4.25	5.00	5.30	5.40	5.50
Investment properties	516,222	820,094	865,100	979,480	1,009,920
Net cash/(debt)	150,868	-161,319	-209,040	-310,700	-320,000
Other assets <sup>3</sup>	-297,695	7,733	14,690	13,300	12,090
Net assets	369,395	666,508	670,760	682,080	702,010
NAV per share (p) <sup>4</sup>	105.5	107.1	107.8	109.7	112.9
Shares in issue (average) <sup>5</sup>	350.0	425.4	622.1	621.6	621.6
Shares in issue (year-end) <sup>5</sup>	350.0	622.5	621.6	621.6	621.6
P/NAV (x)	104.1	102.7	101.9	100.3	97.4
Dividend yield	3.8%	4.6%	4.8%	4.9%	5.0%

Source: Hardman & Co Research

<sup>1</sup>Non-cash accounting of income and assets from follow-on equity

<sup>2</sup>Equating to profits after interest pre revaluation of assets, excluding C share accounting (non-cash) amortisation and other adjustments

<sup>3</sup>2018 includes £298.7m C shares as balancing accounting debit – ultimately converted to ord. shares

<sup>4</sup>EPRA NAV for Civitas equates to IFRS NAV

<sup>5</sup>Excludes C shares, which were all subsequently converted to ordinary shares

## Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legals/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

## Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.



[research@hardmanandco.com](mailto:research@hardmanandco.com)

35 New Broad Street  
London  
EC2M 1NH

+44(0)20 7194 7622

[www.hardmanandco.com](http://www.hardmanandco.com)